Clinical Disparities for Minorities and Foreign-Born Men With Undescended Versus Descended Testicular Germ Cell Tumors.

Abstract:

BACKGROUND:Few reports have been published regarding the outcomes of patients who develop an undescended testicular malignancy (UTM). Our objective was to analyze the sociodemographic and survival outcomes of patients with UTM and those of with descended testicular malignancy (DTM). PATIENTS AND METHODS:All 17 registries constituting the Surveillance, Epidemiology, and End Results (SEER) database were analyzed from 1988 to 2008. Patients with a descended or undescended testis and a diagnosis of nonseminomatous or seminomatous testicular cancer were identified. Descriptive statistical data and multivariate analysis were used to identify the predictors of a UTM diagnosis. The primary outcomes were overall and disease-specific survival. RESULTS:The study cohort included 10,159 men (95.3%) with DTM and 496 (4.7%) with UTM. Patients with UTM were more likely to be older, married, and a minority or foreign born and to have seminoma, a higher rate of node positivity, and a higher SEER stage compared with patients with DTM. The median survival time for patients with UTM was longer than that for patients with to DTM (83.1 vs. 72.5 months; P = .0001), although no difference was found in cancer-specific mortality (P = .34). CONCLUSION:Patients with UTM are more likely to be a minority or foreign born, highlighting a previously unrecognized healthcare disparity that might represent a lack of diagnosis and access to care.

journal_name

Clin Genitourin Cancer

authors

Klaassen Z,Reinstatler L,Wilson SN,Ellington C,Li Q,Terris MK,Moses KA

doi

10.1016/j.clgc.2015.08.004

subject

Has Abstract

pub_date

2016-06-01 00:00:00

pages

e251-5

issue

3

eissn

1558-7673

issn

1938-0682

pii

S1558-7673(15)00218-9

journal_volume

14

pub_type

杂志文章
  • Clinical Significance of Subclassification of Papillary Renal Cell Carcinoma: Comparison of Clinicopathologic Parameters and Oncologic Outcomes Between Papillary Histologic Subtypes 1 and 2 Using the Korean Renal Cell Carcinoma Database.

    abstract:INTRODUCTION:The aims of the present study were to compare the clinicopathologic characteristics between type 1 and type 2 papillary renal cell carcinoma (pRCC) and to evaluate the effect of the subclassification of pRCC on the oncologic outcomes after surgery. MATERIALS AND METHODS:The records of 274 patients with pR...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2016.07.020

    authors: Ha YS,Chung JW,Choi SH,Lee JN,Kim HT,Kim TH,Chung SK,Byun SS,Hwang EC,Kang SH,Hong SH,Chung J,Kwak C,Kim YJ,Kwon TG,Korean Renal Cell Carcinoma Study Group.

    更新日期:2017-04-01 00:00:00

  • Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents.

    abstract:BACKGROUND:Several agents have demonstrated an overall survival (OS) benefit in patients with metastatic castration-resistant prostate cancer (mCRPC); however, the optimal sequencing of these therapies is unknown as a result of a lack of prospective randomized controlled trials. This retrospective study aimed to identi...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2018.02.016

    authors: Angelergues A,Efstathiou E,Gyftaki R,Wysocki PJ,Lainez N,Gonzalez I,Castellano DE,Ozguroglu M,Carbonero IG,Flechon A,Borrega P,Guillot A,Balea BC,Le Moulec S,Esteban E,Munarriz J,Rubio G,Birtle AJ,Delanoy N,Bellmunt

    更新日期:2018-08-01 00:00:00

  • Secondary hormonal therapy in men with castration-resistant prostate cancer.

    abstract:BACKGROUND:Androgen receptor (AR) signaling remains important in castration-resistant prostate cancer (CRPC) and sequential responses to hormonal therapies are observed. Little is known about the factors associated with responsiveness to secondary hormone therapy (HT). METHODS:We retrospectively identified patients wi...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2011.06.006

    authors: Nakabayashi M,Werner L,Oh WK,Regan MM,Kantoff PW,Taplin ME

    更新日期:2011-12-01 00:00:00

  • Small renal masses managed with active surveillance: predictors of tumor growth rate after long-term follow-up.

    abstract:BACKGROUND:The purpose of the study was to evaluate the relationships between the patients' clinical characteristics and the growth pattern of SRMs, and to investigate the predictive factors of tumor growth rates in patients initially managed with AS. MATERIALS AND METHODS:We retrospectively reviewed data from our pro...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2014.08.006

    authors: Schiavina R,Borghesi M,Dababneh H,Bianchi L,Longhi B,Diazzi D,Monti C,La Manna G,Martorana G,Brunocilla E

    更新日期:2015-04-01 00:00:00

  • Management of favorable-risk patients with metastatic renal cell carcinoma: when to start and when to stop targeted therapy.

    abstract::Targeted therapy has changed the treatment of metastatic renal cell carcinoma (mRCC). However, it is unclear if patients need to start systemic therapy immediately or if treatment can be deferred. Identification of the appropriate time to discontinue therapy is also uncertain. We reviewed treatment guidelines and tria...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clgc.2012.06.002

    authors: Powles T,Albers P

    更新日期:2012-12-01 00:00:00

  • TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer.

    abstract:BACKGROUND:Circulating tumor DNA (ctDNA), which can be assessed by liquid biopsy, can provide valuable genomic information that may affect treatment response in prostate cancer. The aim of this study was to characterize TP53 mutations and treatment history in prostate cancer. PATIENTS AND METHODS:This study included 1...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.10.022

    authors: Chapman L,Ledet EM,Barata PC,Cotogno P,Manogue C,Moses M,Christensen BR,Steinwald P,Ranasinghe L,Layton JL,Lewis BE,Sartor O

    更新日期:2020-04-01 00:00:00

  • Programmed Death-Ligand 1 Expression in Muscle-Invasive Bladder Cancer Cystectomy Specimens and Lymph Node Metastasis: A Reliable Treatment Selection Biomarker?

    abstract:BACKGROUND:The programmed death-1 (PD-1) pathway negatively regulates T-cell activation and has an important role in regulating antitumor host immunity. Monoclonal antibodies directed against PD-1 or the PD-1 ligand (PD-L1) have shown activity in several tumor types with preliminary data suggesting a relationship betwe...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2015.12.002

    authors: Mukherji D,Jabbour MN,Saroufim M,Temraz S,Nasr R,Charafeddine M,Assi R,Shamseddine A,Tawil AN

    更新日期:2016-04-01 00:00:00

  • Metabolic syndrome as a peculiar target for management of prostate cancer patients.

    abstract::An interesting and reciprocal association between the metabolic syndrome and prostate cancer has been identified. Metabolic alterations, such as hyperinsulinemia, increased levels of insulin growth factor-1, and insulin resistance could be on the basis of development and progression of many tumors, including prostate ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clgc.2013.04.009

    authors: Conteduca V,Di Lorenzo G,Bozza G,Ardito R,Aieta M

    更新日期:2013-09-01 00:00:00

  • Primary extraosseous ewing sarcoma of the kidney with level III inferior vena cava thrombus.

    abstract::Ewing sarcoma typically presents as a skeletal-based tumor, with rare instances of peripheral primitive neuroectodermal tumor (PNET) arising in the soft tissues. Few examples of organ-based PNETs have been previously described in the literature. These tumors are exceedingly rare as a primary renal neoplasm. To our kno...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.3816/CGC.2009.n.032

    authors: Fergany AF,Dhar N,Budd GT,Skacel M,Garcia JA

    更新日期:2009-10-01 00:00:00

  • Prognostic Value of the VHL, HIF-1α, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study.

    abstract:BACKGROUND:The prognostic value of molecular markers in renal cell carcinoma has been investigated in several studies. Although their value is still not confirmed, various proteins are important. We describe the effect on long-term survival of the status of the von Hippel-Lindau (VHL) hypoxia-inducible factor 1-α (HIF1...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2017.05.016

    authors: Salinas-Sánchez AS,Serrano-Oviedo L,Nam-Cha SY,Roche-Losada O,Sánchez-Prieto R,Giménez-Bachs JM

    更新日期:2017-12-01 00:00:00

  • Global Quality of Life After Curative Treatment for Prostate Cancer: What Matters? A Study Among Members of the Norwegian Prostate Cancer Patient Association.

    abstract:INTRODUCTION:The purpose of this study was to identify factors that are associated with quality of life (QoL) in relapse-free patients after radical prostatectomy or high-dose radiotherapy with or without hormone treatment. PATIENTS AND METHODS:A cross-sectional postal survey among members of the Norwegian Prostate Ca...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2015.07.004

    authors: Fosså SD,Dahl AA

    更新日期:2015-12-01 00:00:00

  • Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase inhibition with sunitinib.

    abstract:BACKGROUND:Carcinoma of the collecting ducts (CDC) of Bellini of the kidney is very rare but is among the most aggressive urologic entities. PATIENTS AND METHODS:Radical nephrectomy revealed CDC in stage pT3a pN2 M0 G3 in 2 male patients. Four courses of adjuvant chemotherapy with cisplatin and gemcitabine were given....

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.3816/CGC.2009.n.010

    authors: Staehler M,Schöppler G,Haseke N,Stadler T,Karl A,Siebels M,Ihrler S,Stief CG

    更新日期:2009-01-01 00:00:00

  • Nucleolin Staining May Aid in the Identification of Circulating Prostate Cancer Cells.

    abstract:INTRODUCTION:Circulating tumor cells (CTCs) have great potential as circulating biomarkers for solid malignancies. Currently available assays for CTC detection rely on epithelial markers with somewhat limited sensitivity and specificity. We found that the staining pattern of nucleolin, a common nucleolar protein in pro...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2016.12.004

    authors: Chalfin HJ,Verdone JE,van der Toom EE,Glavaris S,Gorin MA,Pienta KJ

    更新日期:2017-06-01 00:00:00

  • Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT).

    abstract:BACKGROUND:The objective of this study was to evaluate differences in tolerability in patients with metastatic castration-resistant prostate cancer treated with enzalutamide (ENZA) or abiraterone acetate plus prednisone (AA+P). PATIENTS AND METHODS:This was a phase IV, prospective, open-label, multicenter, real-world ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2019.07.017

    authors: Shore ND,Saltzstein D,Sieber P,Mehlhaff B,Gervasi L,Phillips J,Wong YN,Pei H,McGowan T

    更新日期:2019-12-01 00:00:00

  • Evaluation of Gleason Grade Group 5 in a Contemporary Prostate Cancer Grading System and Literature Review.

    abstract:INTRODUCTION:The aim of this study was to validate contemporary grading systems, in particular, the Gleason grade group (GGG) 5. PATIENTS AND METHODS:We retrospectively reviewed the clinicopathologic data of 176 patients who underwent radical prostatectomy and whose pathologic results were GGG 4 or 5. The endpoints we...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2020.08.001

    authors: Kamitani R,Matsumoto K,Kosaka T,Takeda T,Hashiguchi A,Tanaka N,Morita S,Mizuno R,Shinojima T,Asanuma H,Oya M

    更新日期:2020-08-07 00:00:00

  • Comparison of Surgery and Radiation as Local Treatments in the Risk of Locoregional Complications in Men Subsequently Dying From Prostate Cancer.

    abstract:INTRODUCTION:Late locoregional complications in prostate cancer (PCa) affect quality of life and require medical interventions. Our objective was to compare late locoregional complications in men dying of castration-resistant PCa (CRPC) who previously received external-beam radiotherapy (EBRT) to radical prostatectomy ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2017.08.011

    authors: Hu J,Aprikian AG,Cury FL,Vanhuyse M,Zakaria AS,Richard PO,Perreault S,Dragomir A

    更新日期:2017-09-05 00:00:00

  • Spontaneous intraperitoneal perforation of the bladder: a late complication of radiation therapy for prostate cancer.

    abstract::The spontaneous intraperitoneal rupture of the urinary bladder is an extremely rare and life-threatening event. Often, there are difficulties in establishing the diagnosis. A patient with spontaneous perforation of the urinary bladder, 17 years after successful treatment of an adenocarcinoma of the prostate by pelvic ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.3816/CGC.2007.n.006

    authors: Ketata S,Boulaire JL,Al-Ahdab N,Bargain A,Damamme A

    更新日期:2007-03-01 00:00:00

  • Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480.

    abstract:BACKGROUND:Scatter factor, also known as hepatocyte growth factor (SF/HGF), is a polypeptide growth factor thought to be important in the growth and spread of prostatic carcinoma. PATIENTS AND METHODS:Scatter factor/HGF levels in pretreatment plasma samples from 171 men with metastatic hormone-refractory prostate canc...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.3816/CGC.2006.n.006

    authors: Humphrey PA,Halabi S,Picus J,Sanford B,Vogelzang NJ,Small EJ,Kantoff PW

    更新日期:2006-03-01 00:00:00

  • Testicular Cancer Biomarkers: A Role for Precision Medicine in Testicular Cancer.

    abstract::Testicular germ cell tumors (TGCTs) represent the most common solid tumors among men aged 15 to 34 years. Fortunately, recent advances have made testicular cancer a highly curable disease. Despite the high cure rates, there are still several areas in testis cancer care where treatment decisions are controversial and g...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clgc.2018.10.007

    authors: Leão R,Ahmad AE,Hamilton RJ

    更新日期:2019-02-01 00:00:00

  • Gynecologic Organ Involvement During Radical Cystectomy for Bladder Cancer: Is It Time to Routinely Spare the Ovaries?

    abstract:PURPOSE:To determine a subset of women who could undergo ovary-sparing radical cystectomy (OSRC) for bladder cancer without compromising oncologic safety. PATIENTS AND METHODS:A retrospective review was performed of 164 consecutive women who underwent cystectomy at a single tertiary-care center from 1997 to 2018. Clin...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2018.10.009

    authors: Taylor BL,Matrai CE,Smith AL,Ayangbesan A,Xia L,Golombos DM,Mosquera JM,Nicolas J,Robinson BD,Scherr DS,Khani F

    更新日期:2019-02-01 00:00:00

  • Prognostic Value of Body Mass Index According to Histologic Subtype in Nonmetastatic Renal Cell Carcinoma: A Large Cohort Analysis.

    abstract:OBJECTIVE:The objective of our study was to assess the prognostic value of body mass index (BMI) according to histologic subtype in nonmetastatic renal cell carcinoma (RCC), based on a large multicenter experience. METHODS:A total of 2769 patients with nonmetastatic RCC at the time of surgery were enrolled from 5 Kore...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2015.04.012

    authors: Lee WK,Hong SK,Lee S,Kwak C,Oh JJ,Jeong CW,Kim YJ,Kang SH,Hong SH,Byun SS

    更新日期:2015-10-01 00:00:00

  • Serum Proteomics on the Basis of Discovery of Predictive Biomarkers of Response to Androgen Deprivation Therapy in Advanced Prostate Cancer.

    abstract:BACKGROUND:We investigated the serum proteome of hormone-sensitive prostate cancer patients to determine candidate biomarkers associated with androgen deprivation therapy (ADT) efficacy. PATIENTS AND METHODS:Serum proteomes generated using isobaric mass tags for relative and absolute quantitation were analyzed using r...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.03.006

    authors: Kohli M,Oberg AL,Mahoney DW,Riska SM,Sherwood R,Zhang Y,Zenka RM,Sahasrabudhe D,Qin R,Zhang S

    更新日期:2019-08-01 00:00:00

  • Adjuvant therapy of renal cell carcinoma.

    abstract::Metastatic renal cell carcinoma (RCC) has a highly variable natural history and carries a dismal prognosis. Unlike many other tumors, RCC is generally unresponsive to cytotoxic, hormonal, and radiation adjuvant therapies after cytoreductive surgery. Different modalities of treatment have been tried and tested with mod...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CGC.2006.n.028

    authors: Yap TA,Eisen TG

    更新日期:2006-09-01 00:00:00

  • Cardiovascular and Metabolic Toxicity of Abiraterone in Castration-resistant Prostate Cancer: Post-marketing Experience.

    abstract:INTRODUCTION:Abiraterone improves survival in metastatic castration-resistant prostate cancer (mCRPC) but may result in the development or worsening of comorbid conditions. We assessed the course of these conditions in patients receiving abiraterone in clinical practice and compared outcomes with those in clinical tria...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.03.001

    authors: Tsao PA,Estes JP,Griggs JJ,Smith DC,Caram MEV

    更新日期:2019-06-01 00:00:00

  • A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.

    abstract:UNLABELLED:The present multicenter phase II study evaluated the efficacy and safety of weekly docetaxel as second-line chemotherapy for metastatic urothelial carcinoma. Weekly docetaxel was well tolerated but demonstrated modest activity, with a response rate of 6%, a median progression-free survival (PFS) of 1.4 month...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2015.09.008

    authors: Kim YS,Lee SI,Park SH,Park S,Hwang IG,Lee SC,Sun JM,Lee J,Lim HY

    更新日期:2016-02-01 00:00:00

  • Unravelling Adrenal Oncocytic Neoplasm.

    abstract::Oncocytic neoplasms are rare tumors arising in the adrenal glands and usually considered as nonfunctional and benign. We report 4 cases of adrenal oncocytic neoplasm. The paucity of literature describing this entity increases the chance for misdiagnosis. Confirmatory diagnosis is by tissue sampling with adrenalectomy ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clgc.2018.10.011

    authors: Virarkar M,Patnana M,Vikram R,Bhargava P,Birkenfeld E,Sagebiel T

    更新日期:2019-02-01 00:00:00

  • Identification of Differential Patterns of Oxidative Biomarkers in Prostate Cancer Progression.

    abstract:INTRODUCTION:Oxidative stress has been found to be associated with the progression of prostate cancer (PCa); however, human studies which identify differential roles of each oxidation pathway in PCa progression are lacking. We aimed to identify which oxidative stress markers, specifically lipid and global oxidation and...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.09.014

    authors: Wu T,Kasper S,Wong RM,Bracken B

    更新日期:2020-04-01 00:00:00

  • Salvage Focal Cryotherapy Offers Similar Short-term Oncologic Control and Improved Urinary Function Compared With Salvage Whole Gland Cryotherapy for Radiation-resistant or Recurrent Prostate Cancer.

    abstract:BACKGROUND:We compared the short-term oncologic and functional outcomes of salvage focal cryotherapy (SFC) with those of salvage total cryotherapy (STC) for radiotherapy (RT)-persistent/recurrent prostate cancer. MATERIALS AND METHODS:We queried the Cryo On-Line Database registry for men who had undergone SFC and STC ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.11.009

    authors: Tan WP,ElShafei A,Aminsharifi A,Khalifa AO,Polascik TJ

    更新日期:2020-06-01 00:00:00

  • Correlation Between the Timing of Diagnostic Ureteroscopy and Intravesical Recurrence in Upper Tract Urothelial Cancer.

    abstract:UNLABELLED:To identify the effects of diagnostic ureteroscopy on intravesical recurrence, 104 patients who had undergone radical nephroureterectomy were analyzed. The number of patients with intravesical recurrence was 34 (32.6%) at a mean of 37 months. Multivariate Cox model analysis revealed that delayed nephroureter...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2015.07.008

    authors: Lee JK,Kim KB,Park YH,Oh JJ,Lee S,Jeong CW,Jeong SJ,Hong SK,Byun SS,Lee SE

    更新日期:2016-02-01 00:00:00

  • Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.

    abstract::The use of sunitinib in dialysis patients is poorly described but is of clinical importance. We report 2 cases of patients receiving sunitinib for metastatic renal cell carcinoma while undergoing dialysis. The first patient is undergoing hemodialysis and, though responding to sunitinib, is having significant fatigue a...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.3816/CGC.2009.n.035

    authors: Vickers MM,Heng DY,Hemmelgarn B,Eigl BJ

    更新日期:2009-10-01 00:00:00